<DOC>
	<DOCNO>NCT00004203</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness oxaliplatin treat patient metastatic bladder cancer .</brief_summary>
	<brief_title>Oxaliplatin Treating Patients With Metastatic Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate , duration response , overall survival patient metastatic urothelial carcinoma treat oxaliplatin . II . Determine toxicity , include objective measurement neurotoxicity , oxaliplatin patient treat regimen . OUTLINE : This multicenter study . Patients stratify platinum therapy status ( platinum sensitive v platinum resistant ) . Patients receive oxaliplatin IV 2 hour day 1 . Courses repeat every 3 week absence disease progression , illness would preclude administration study drug , unacceptable toxicity . Patients follow minimum 2 year death . PROJECTED ACCRUAL : A total 12-37 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven metastatic urothelial carcinoma Bidimensionally measurable disease Platinum sensitive OR platinum resistant Platinum sensitive disease : No prior platinum contain regimen OR Progressive recurrent disease 6 month respond platinum contain regimen Platinum resistant disease : Progressive recurrent disease within 6 month platinum contain regimen ( cisplatin carboplatin ) No brain metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Karnofsky 50100 % Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin normal SGOT SGPT great 2.5 time upper limit normal Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 30 mL/min Cardiovascular : No uncontrolled concurrent illness include , limited : Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Other : No clinical evidence neuropathy bad grade 1 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study No allergy platinum compound antiemetic No uncontrolled concurrent illness include , limited , active infection PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent colony stimulate factor first course study therapy Chemotherapy : See Disease Characteristics One prior chemotherapy regimen metastatic disease allow Prior neoadjuvant adjuvant chemotherapy regimen allow interval therapy first therapy metastatic disease least 6 month At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy Surgery : Not specify Other : No concurrent investigational agent No HIV positive patient receive antiretroviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>recurrent transitional cell cancer renal pelvis ureter</keyword>
</DOC>